Clinical Trials Logo

Islet Cell Transplantation clinical trials

View clinical trials related to Islet Cell Transplantation.

Filter by:
  • None
  • Page 1

NCT ID: NCT03779139 Recruiting - Diabetes Mellitus Clinical Trials

Intra-Portal Alone Versus Intra- and Extra-Portal Transplantation of Pancreatic Islets After Total Pancreatectomy for Chronic Pancreatitis

iSite
Start date: August 1, 2019
Phase: N/A
Study type: Interventional

Randomized pilot trial of patients (n=30) undergoing Total Pancreatectomy and Islet AutoTransplant (TPIAT). Patients with islet harvest of greater than 5000 islet equivalents/kg body weight will be randomized to receive a portion of their islets into an omental pouch. For outcomes related to islet function, a group of normal volunteers (n=15) will be studied as a comparator group.

NCT ID: NCT03106246 Recruiting - Type2 Diabetes Clinical Trials

Circulating Extracellular Vesicles Released by Human Islets of Langerhans

Start date: December 2016
Phase: N/A
Study type: Observational

Beta-cells release extracellular vesicles (EV) and exosomes under normal and pathophysiologic conditions. These EV contain beta-cell specific autoantigens which may trigger the immune response at the initiation of type 1 diabetes. In this study, beta-cell derived EV will be detected and characterized in human blood samples.

NCT ID: NCT03079921 Active, not recruiting - Hypoglycemia Clinical Trials

Adrenergic System in Islet Transplantation

Start date: January 20, 2017
Phase: Early Phase 1
Study type: Interventional

To determine the effect of sympathetic neural and hormonal (epinephrine) input on islet cell hormonal responses to insulin-induced hypoglycemia in type 1 diabetic recipients of intrahepatic islet transplantation. We hypothesize that α-adrenergic (neural) blockage will abolish insulin-mediated suppression of C-peptide, attenuating α-cell glucagon secretion during hypoglycemia, and that β-adrenergic (hormonal) blockage will have no effect. Glucose counterregulatory responses will be measured during hyperinsulinemic euglycemic-hypoglycemic clamps on three occasions with randomized, double-blind administration of the α-adrenergic blocker phentolamine, the β-adrenergic blocker propranolol, or placebo. The demonstration of neural rather than hormonal regulation of the transplanted islet cell response to hypoglycemia is critical for understanding the mechanism for protection from hypoglycemia afforded by intrahepatically transplanted.

NCT ID: NCT03047200 Withdrawn - Type 1 Diabetes Clinical Trials

Pancreatic Islet Cell Transplantation After Kidney Transplantation - A Novel Approach to Immunosupression

Start date: July 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to further test islet cell transplant in patients who have had a kidney transplant. This study will also evaluate the safety and effectiveness of the anti-rejection medications used to prevent rejection after your islet cell transplant.

NCT ID: NCT00530686 Completed - Type 1 Diabetes Clinical Trials

Pancreatic Islet Cell Transplantation - A Novel Approach to Improve Islet Quality and Engraftment

Start date: July 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess a novel approach to immunosuppression in allogenic pancreatic islet cell transplant recipients. In addition, the study aims to assess remote site islet processing with culture for pancreatic islet cell transplantation in human subjects.